Jaguar Health Strengthens IP Protection with New European and Australian Patents

Jaguar Health, Inc. (NASDAQ:JAGX) has announced the issuance of new patents in Europe and Australia, enhancing the company's intellectual property protection for crofelemer. Crofelemer is a plant-based prescription drug targeting rare disease indications such as Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs), specifically microvillus inclusion disease (MVID).

The European patent covers methods for treating SBS, bile acid diarrhea, and diarrhea related to small intestine resection or gallbladder removal with chloride-ion transport inhibitors like crofelemer. In Australia, the new patent covers methods for preventing and treating diarrhea associated with CDDs using crofelemer.

Lisa Conte, Jaguar's CEO, emphasized that these new patents further solidify crofelemer's IP protection. Jaguar Health is supporting proof-of-concept studies for crofelemer in regions including the US, EU, and MENA, with results expected in 2024 and 2025. The studies aim to offer early patient access based on specific EU country guidelines.